Drug Profile


Alternative Names: GV1001; hTERT RNA vaccine - KAEL-GemVax; LucaVax; Telomerase peptide vaccine - KAEL-GemVax; TeloVac

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmexa
  • Developer Affitech A/S; Cancer Research UK; KAEL-GemVax; Lytix Biopharma; Norwegian Radium Hospital; Pharmexa
  • Class Cancer vaccines; Peptide fragments; Ribonucleoproteins
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase II Alzheimer's disease; Benign prostatic hyperplasia; Non-small cell lung cancer
  • Phase I/II Malignant melanoma
  • No development reported Solid tumours
  • Discontinued Hepatocellular carcinoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Adjuvant therapy) in Norway (Intradermal, Injection)
  • 01 Jun 2017 Phase-II clinical trials in Alzheimer's disease (Treatment-experienced) in South Korea (SC) (NCT03184467)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top